+

WO2003101425A3 - Articles polymeres contenant des agents therapeutiques - Google Patents

Articles polymeres contenant des agents therapeutiques Download PDF

Info

Publication number
WO2003101425A3
WO2003101425A3 PCT/US2003/017536 US0317536W WO03101425A3 WO 2003101425 A3 WO2003101425 A3 WO 2003101425A3 US 0317536 W US0317536 W US 0317536W WO 03101425 A3 WO03101425 A3 WO 03101425A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoarticles
therapeutic agent
containing polymeric
drug
covalently attached
Prior art date
Application number
PCT/US2003/017536
Other languages
English (en)
Other versions
WO2003101425A2 (fr
WO2003101425A8 (fr
Inventor
Stephen E Barry
Andrew A Goodwin
Rachel Decor
Original Assignee
Alnis Biosciences Inc
Stephen E Barry
Andrew A Goodwin
Rachel Decor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnis Biosciences Inc, Stephen E Barry, Andrew A Goodwin, Rachel Decor filed Critical Alnis Biosciences Inc
Priority to EP03741863A priority Critical patent/EP1531868A2/fr
Priority to CA002487720A priority patent/CA2487720A1/fr
Priority to AU2003273272A priority patent/AU2003273272A1/en
Priority to JP2004508783A priority patent/JP2005535604A/ja
Publication of WO2003101425A2 publication Critical patent/WO2003101425A2/fr
Priority to US10/995,880 priority patent/US20050129769A1/en
Publication of WO2003101425A3 publication Critical patent/WO2003101425A3/fr
Publication of WO2003101425A8 publication Critical patent/WO2003101425A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des articles polymères hydrophiles comprenant une structure polymère et un ou plusieurs agents thérapeutiques, tels que des molécules médicamenteuses ou de conjugués médicamenteux. Les articles peuvent en outre éventuellement comprendre des éléments de reconnaissance qui se fixent à des structures biomoléculaires exprimées sur certaines cellules ou sur certains tissus, pour faciliter le ciblage et/ou l'administration.
PCT/US2003/017536 2002-06-03 2003-06-03 Articles polymeres contenant des agents therapeutiques WO2003101425A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03741863A EP1531868A2 (fr) 2002-06-03 2003-06-03 Agents therapeutiques contenant des nano-polymeres
CA002487720A CA2487720A1 (fr) 2002-06-03 2003-06-03 Agent therapeutique contenant des nanoarticles polymeriques
AU2003273272A AU2003273272A1 (en) 2002-06-03 2003-06-03 Therapeutic agent-containing polymeric nanoarticles
JP2004508783A JP2005535604A (ja) 2002-06-03 2003-06-03 治療剤を含むポリマーナノ物品
US10/995,880 US20050129769A1 (en) 2002-06-03 2004-11-22 Polymeric articles for carrying therapeutic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38553702P 2002-06-03 2002-06-03
US60/385,537 2002-06-03
US46316203P 2003-04-16 2003-04-16
US60/463,162 2003-04-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/995,880 Continuation-In-Part US20050129769A1 (en) 2002-06-03 2004-11-22 Polymeric articles for carrying therapeutic agents

Publications (3)

Publication Number Publication Date
WO2003101425A2 WO2003101425A2 (fr) 2003-12-11
WO2003101425A3 true WO2003101425A3 (fr) 2005-03-17
WO2003101425A8 WO2003101425A8 (fr) 2005-04-28

Family

ID=29715373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017536 WO2003101425A2 (fr) 2002-06-03 2003-06-03 Articles polymeres contenant des agents therapeutiques

Country Status (5)

Country Link
EP (1) EP1531868A2 (fr)
JP (1) JP2005535604A (fr)
AU (1) AU2003273272A1 (fr)
CA (1) CA2487720A1 (fr)
WO (1) WO2003101425A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027873A2 (fr) * 2003-06-20 2005-03-31 Alnis Biosciences, Inc. Nanoarticles therapeutiques
WO2005065724A1 (fr) * 2003-12-30 2005-07-21 Alnis Biosciences, Inc. Preparations a base de complexes d'ions paramagnetiques
EP1718341A2 (fr) * 2004-01-20 2006-11-08 Alnis Biosciences, Inc. Articles comprenant un materiau magnetique et des agents bioactifs
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP2111872B1 (fr) * 2004-07-05 2020-12-23 Ascendis Pharma GmbH Conjugués d`hydrogel
ES2387195T3 (es) * 2005-05-27 2012-09-17 Royer Biomedical, Inc. Matrices de polímero y métodos de fabricación y uso de las mismas
EP2399610A3 (fr) * 2007-09-24 2012-09-05 Bar-Ilan University Nanoparticules en polymère recouvertes d'oxyde de métal magnétique et leurs utilisations
WO2010042638A2 (fr) 2008-10-07 2010-04-15 Young Bok Lee Conjugués hpma-docétaxel ou gemcitabine et utilisations associées
ES2505890T3 (es) 2008-12-16 2014-10-10 Fundació Privada Institut Català De Nanotecnologia Conjugados que comprenden nanopartículas recubiertas con compuestos que contienen platino
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
KR20120089843A (ko) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
BR112012008772A2 (pt) * 2009-10-13 2017-06-20 Rexahn Pharmaceuticals Inc sistemas poliméricos para a liberação de agentes anti-câncer
CN101864071B (zh) * 2010-05-21 2011-12-21 北京中海康医药科技发展有限公司 聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
US20120141551A1 (en) * 2010-12-02 2012-06-07 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
WO2013036931A1 (fr) 2011-09-08 2013-03-14 Western University Of Health Sciences Liposomes ciblés en thérapie cancéreuse
PL221351B1 (pl) * 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
US20170333304A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel Particles, Compositions, and Methods
US11666515B2 (en) 2018-03-28 2023-06-06 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5415864A (en) * 1990-04-18 1995-05-16 University Of Utah Research Foundation Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5702727A (en) * 1993-02-22 1997-12-30 Alza Corporation Compositions and methods for the oral delivery of active agents
EP0838224A2 (fr) * 1996-10-02 1998-04-29 Kuraray Co., Ltd. Conjugués de polymère - médicament avec in lien clivable par des enzymes
WO2000009088A1 (fr) * 1998-08-14 2000-02-24 Incept Llc Systemes d'administration de medicaments au moyen d'hydrogels composites
WO2001015738A2 (fr) * 1999-09-02 2001-03-08 Rice University Materiaux hydrogels produisant du monoxyde d'azote
WO2001078786A2 (fr) * 2000-04-14 2001-10-25 Alnis Biosciences, Inc. Nanoparticules renfermant des peptides a haute affinite

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5415864A (en) * 1990-04-18 1995-05-16 University Of Utah Research Foundation Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5702727A (en) * 1993-02-22 1997-12-30 Alza Corporation Compositions and methods for the oral delivery of active agents
EP0838224A2 (fr) * 1996-10-02 1998-04-29 Kuraray Co., Ltd. Conjugués de polymère - médicament avec in lien clivable par des enzymes
WO2000009088A1 (fr) * 1998-08-14 2000-02-24 Incept Llc Systemes d'administration de medicaments au moyen d'hydrogels composites
WO2001015738A2 (fr) * 1999-09-02 2001-03-08 Rice University Materiaux hydrogels produisant du monoxyde d'azote
WO2001078786A2 (fr) * 2000-04-14 2001-10-25 Alnis Biosciences, Inc. Nanoparticules renfermant des peptides a haute affinite

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOUHADIR K H ET AL: "Hydrogels for combination delivery of antineoplastic agents", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 19, 1 October 2001 (2001-10-01), pages 2625 - 2633, XP004296082, ISSN: 0142-9612 *
BOUHADIR KAMAL H ET AL: "Sustained and controlled release of daunomycin from cross-linked poly(aldehyde guluronate) hydrogels", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 89, no. 7, July 2000 (2000-07-01), pages 910 - 919, XP002261385, ISSN: 0022-3549 *
CAIOLFA V R ET AL: "Polymer-bound camptothecin: initial biodistribution and antitumour activity studies", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 65, no. 1-2, March 2000 (2000-03-01), pages 105 - 119, XP004190316, ISSN: 0168-3659 *
DENNY WILLIAM A ET AL: "The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 50, no. 4, April 1998 (1998-04-01), pages 387 - 394, XP009020713, ISSN: 0022-3573 *
GOLDBERG EUGENE P: "POLYMERIC AFFINITY DRUGS FOR CARDIOVASCULAR, CANCER AND UROLITHIASIS THERAPY", 173RD;NEW ORLEANS, LA, USA MAR 20-25 1977, vol. 18, no. 1, March 1977 (1977-03-01), Am Chem Soc Div Polym Chem Prepr Mar 1977, pages 575 - 580, XP009020428 *
LLOYD JOHN B ET AL: "SOLUBLE SYNTHETIC POLYMERS AS TARGETABLE AGENTS FOR INTRACELLULAR DRUG RELEASE", PAP PRESENTED AT THE POLYM AS DRUG RELEASE AGENTS SYMP;LONDON, ENGL MAR 23 1983, vol. 15, no. 4, 23 March 1983 (1983-03-23), Br Polym J Dec 1983, pages 158 - 159, XP009020432 *
VERVOORT LIESBETH ET AL: "Inulin hydrogels as carriers for colonic drug targeting: I. Synthesis and characterization of methacrylated inulin and hydrogel formation", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 14, no. 12, December 1997 (1997-12-01), pages 1730 - 1737, XP009020453, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
AU2003273272A1 (en) 2003-12-19
JP2005535604A (ja) 2005-11-24
EP1531868A2 (fr) 2005-05-25
WO2003101425A2 (fr) 2003-12-11
WO2003101425A8 (fr) 2005-04-28
AU2003273272A8 (en) 2003-12-19
CA2487720A1 (fr) 2003-12-11

Similar Documents

Publication Publication Date Title
WO2003101425A8 (fr) Articles polymeres contenant des agents therapeutiques
WO2003011226A3 (fr) Produits et excipients pour l'administration de medicaments
WO2007041584A3 (fr) Capteurs implantables, pompes implantables et associations de medicaments empechant la formation de cicatrices
WO2005044224A3 (fr) Systeme d'administration de medicament, faisant appel a des nanocoques polymeres
WO2005099667A3 (fr) Compositions d'administration de medicaments
WO2007076371A3 (fr) Compositions de supports a noyau hydrophobe pour l'administration d'agents therapeutiques, et procedes de preparation et d'utilisation
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
WO2004021968A3 (fr) Solution destinee a une application ungueale et peri-ungueale
WO2004037316A3 (fr) Systeme de distribution de nanoparticules
WO2005112886A3 (fr) Procedes et articles pour l’administration d’agents therapeutiques
EP1201230A3 (fr) Système d'administration transdermique en solution comprenant un vasodilatateur
WO2005025499A3 (fr) Compositions hydrophobes de medicaments, contenant un activateur de reconstitution
WO2004000389A3 (fr) Microperforateur a dissolution rapide pour administration de produits pharmaceutiques et autres applications
WO2005051295A3 (fr) Conjugues polymeres ramifies de facon asymetrique et analyses de microreseaux
WO2003084520A3 (fr) Preparation pharmaceutique contenant oxycodone et naloxone
AU2003217531A1 (en) Ocular drug delivery systems and use thereof
WO2005111238A3 (fr) Delivrance intracellulaire oligonucleotides therapeutiques mediee par des aptameres
WO2004093795A3 (fr) Compositions d'administration de combinaisons de medicaments
WO2004091446A3 (fr) Systemes de mise en place de dispositifs medicaux
EP1594477A4 (fr) Apport de medicament actif dans le tube digestif
EP1941839A3 (fr) Dispositifs médicaux avec élément coupant
GB0221942D0 (en) Drug delivery
EP1691785A4 (fr) Excipients pour transport de medicaments
WO2006138099A3 (fr) Formulation de proteines de morphogenese osseuse
WO2003028696A8 (fr) Compositions pour l'administration de combinaisons medicinales

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10995880

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2487720

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004508783

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003741863

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 50/2003 UNDER (71) THE NAME/ADDRESS SHOULD READ "ALNIS BIOSCIENCES, INC."

WWP Wipo information: published in national office

Ref document number: 2003741863

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003741863

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载